In preparation for the CADTH submission for Gilead’s new drug filgotinib, The Arthritis Society in collaboration with the Canadian Arthritis Patient Alliance developed a survey to hear directly from people living with rheumatoid arthritis (RA) about their experiences with RA and any experiences taking filgotinib. The survey was shared via e-mails, social media and the CAPA newsletter through our respective Canadian networks and communities. The survey was open from July 27 until August 21, 2020. We are now pleased to share the submission with our readers here.